Product Description
ABV-1601 leverages the same active pharmaceutical ingredient (API) and mechanism of action as ABV-1504 and ABV-1505. The Phase I/II clinical trial for treating depression in cancer patients was approved by the U.S. FDA in December 2018. The Phase I clinical study, led by Scott Irwin M.D., Ph.D. of Cedar-Sinai Medical Center, was initiated in March of 2023. (Sourced from: https://abvcpharma.com/?page_id=16981)
Mechanisms of Action: NET Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: ABVC
Company Location: Western America
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Depressive Disorder
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/14/2024 |
News Article |
ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones |
|
08/15/2024 |
News Article |
ABVC BioPharma, Inc. Reports Strong Q2 2024 Financial Results and Strategic Achievements |
|
12/05/2023 |
News Article |
ABVC BioPharma Shares Insights from Dr. Scott Irwin of Cedars-Sinai Medical Center over Depression in Cancer Patients Clinical Trials |